logo-loader

Full interview: LexaGene Holdings makes improvements on its coronavirus analyzer to accelerate submission to FDA

Published: 15:03 11 Mar 2020 EDT

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Jack Regan tells Proactive it is accelerating the submission of its LX Analyzer to the FDA as the coronavirus (COVID-19) outbreak expands.

Regan says is 'taking every measure to accelerate' its Emergency Use Authorization (EUA) submission to the FDA, like hiring consultants to help guide regulatory procedures, as well as improving its manufacturing and serviceability.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

14 hours, 8 minutes ago